Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 460,000 | 85.9% |
| Gross Profit | -56M | 11.1% |
| Cost of Revenue | 57M | 11.5% |
| Operating expense | 141M | 8.3% |
| Net Income | -161M | 12% |
| EBITDA | -138M | 8.2% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.44B | 5.8% |
| Total Liabilities | 1.45B | 2.5% |
| Shares Outstanding | 120,000 | 7.7% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -101M | 2.2% |
| Cash from investing | -45M | 93.1% |
| Cash from financing | 3.4M | 99.6% |
EPS
Financial Highlights for Cytokinetics in Q3 '24
Cytokinetics reported a revenue of 460,000, which is a 85.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -56M, marking a -11.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 57M, a 11.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 141M, showing a 8.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -161M, showing a -12% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -138M, showing a -8.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cytokinetics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
